These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 36498669)

  • 1. Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis.
    Gu S; Hu X; Shi L; Zhen X; Sun X; Huang M; Gu Y; Dong H
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Gu S; Hu X; Zhen X; Shi L; Shao H; Sun X; Gu Y; Huang M; Dong H
    J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36143082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
    Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
    Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
    Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
    Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
    Chakravarty A; Rastogi M; Dhankhar P; Bell KF
    J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B; Cameron C; Singh SR; Yu C; Ahuja T; Welton NJ; Dahl M
    Open Med; 2011; 5(1):e35-48. PubMed ID: 22046219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis.
    Yang S; Zhao L; He W; Mi Y
    Drugs; 2022 Sep; 82(14):1469-1480. PubMed ID: 36129662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
    Palmer SC; Mavridis D; Nicolucci A; Johnson DW; Tonelli M; Craig JC; Maggo J; Gray V; De Berardis G; Ruospo M; Natale P; Saglimbene V; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque L; Lloyd A; Ahmad N; Liu Y; Tiv S; Wiebe N; Strippoli GF
    JAMA; 2016 Jul; 316(3):313-24. PubMed ID: 27434443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
    Scheen AJ
    Presse Med; 2023 Mar; 52(1):104158. PubMed ID: 36565754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
    Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
    Rathmann W; Bongaerts B; Kostev K
    Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.